Renin Angiotensin System Blockade in Renal Transplant Patients With Presence of PECs in Urine

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

By means of a personalized medicine strategy, investigators are going to evaluate if the treatment with an angiotensin II receptor antagonist (ARAII) in renal transplant patients with the presence of renal progenitor cells (PECs) in the urine is able to prevent the expected loss of glomerular filtration (GFR) observed in this subgroup of patients. In addition, investigators intend to deepen the mechanisms of glomerular damage and glomerular repair involved in the process of chronic allograft damage.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Josep M Cruzado
• Treatments: Valsartan

Criteria

Inclusion Criteria:

• Written informed consent

• Stable renal function understood as a variation of eGFR of less than 15% in the last 3 months

• Immunosuppression maintenance based on tacrolimus and MMF / MPA

Exclusion Criteria:

• Chronic active infection by HCV, HBV, HIV.

• Treatment with inhibitors of the renin angiotensin system.

• Double kidney transplant or combined with another organ.

• Immunosuppression of maintenance other than tacrolimus and MMF / MPA.

• eGFR <20 ml / min / 1.73m2.

• History of allergy or intolerance to inhibitors of the renin angiotensin system.

• Physically fertile women who plan to become pregnant, are pregnant and

/ or breast-feeding, or who do not want to use effective contraception during their participation in the study.

• Any other medical condition that, in the opinion of the investigator, based on the counting or review of clinical records, could affect the completion of the study, including, but not limited to, visual problems or cognitive impairment.